{"Title": "The use of dipeptide derivatives of 5-aminolaevulinic acid promotes their entry to tumor cells and improves tumor selectivity of photodynamic therapy", "Year": 2015, "Source": "Mol. Cancer Ther.", "Volume": "14", "Issue": 2, "Art.No": null, "PageStart": 440, "PageEnd": 451, "CitedBy": 6, "DOI": "10.1158/1535-7163.MCT-13-1084", "Link": "https://www.scopus.com/inward/record.uri?partnerID=HzOxMe3b&scp=84923385849&origin=inward", "Abstract": "\u00a92014 AACR.The use of endogenous protoporphyrin IX generated after administration of 5-aminolaevulinic acid (ALA) has led to many applications in photodynamic therapy (PDT). However, the bioavailability of ALA is limited by its hydrophilic properties and limited cell uptake. A promising approach to optimize the efficacy of ALA-PDT is to deliver ALA in the form of prodrugs to mask its hydrophilic nature. The aim of this work was to evaluate the potential of two ALA dipeptide derivatives, N-acetyl terminated leucinyl-ALA methyl ester (Ac-Leu-ALA-Me) and phenylalanyl-ALA methyl ester (Ac-Phe-ALA-Me), for their use in PDT of cancer, by investigating the generation of protoporphyrin IX in an oncogenic cell line (PAM212-Ras), and in a subcutaneous tumor model. In our in vitro studies, both derivatives were more effective than ALA in PDT treatment, at inducing the same protoporphyrin IX levels but at 50- to 100-fold lower concentrations, with the phenylalanyl derivative being the most effective. The efficient release of ALA from Ac-Phe-ALA-Me appears to be consistent with the reported substrate and inhibitor preferences of acylpeptide hydrolase. In vivo studies revealed that topical application of the peptide prodrug Ac-Phe-ALA-Me gave greater selectivity than with ALA itself, and induced tumor photodamage, whereas systemic administration improved ALA-induced porphyrin generation in terms of equivalent doses administered, without induction of toxic effects. Our data support the possibility of using particularly Ac-Phe-ALA-Me both for topical treatment of basal cell carcinomas and for systemic administration. Further chemical fine-tuning of this prodrug template should yield additional compounds for enhanced ALA-PDT with potential for translation to the clinic.", "AuthorKeywords": null, "IndexKeywords": ["Aminolevulinic Acid", "Animals", "Cell Line, Tumor", "Cell Survival", "Dipeptides", "Humans", "Kinetics", "Male", "Mice, Inbred BALB C", "Microscopy, Fluorescence", "Neoplasms", "Photochemotherapy", "Porphyrins", "ras Proteins"], "DocumentType": "Journal", "PublicationStage": null, "OpenAccess": 1, "EID": "2-s2.0-84923385849", "SubjectAreas": [["Oncology", "MEDI", "2730"], ["Cancer Research", "BIOC", "1306"]], "AuthorData": {"6508370574": {"Name": "Di Venosa G.", "AuthorID": "6508370574", "AffiliationID": "60009065, 60001563, 60057053", "AffiliationName": "Centrode Investigaciones Sobre Porfirinas Y Porfirias (CIPYP), Hospital de Cl\u00ednicas Jos\u00e9 de San Mart\u00edn, University of Buenos Aires"}, "56073485600": {"Name": "Vallecorsa P.", "AuthorID": "56073485600", "AffiliationID": "60009065, 60001563, 60057053", "AffiliationName": "Centrode Investigaciones Sobre Porfirinas Y Porfirias (CIPYP), Hospital de Cl\u00ednicas Jos\u00e9 de San Mart\u00edn, University of Buenos Aires"}, "24329749800": {"Name": "Mamone L.", "AuthorID": "24329749800", "AffiliationID": "60009065, 60001563, 60057053", "AffiliationName": "Centrode Investigaciones Sobre Porfirinas Y Porfirias (CIPYP), Hospital de Cl\u00ednicas Jos\u00e9 de San Mart\u00edn, University of Buenos Aires"}, "35591371000": {"Name": "Batlle A.", "AuthorID": "35591371000", "AffiliationID": "60009065, 60001563, 60057053", "AffiliationName": "Centrode Investigaciones Sobre Porfirinas Y Porfirias (CIPYP), Hospital de Cl\u00ednicas Jos\u00e9 de San Mart\u00edn, University of Buenos Aires"}, "7006062408": {"Name": "Casas A.", "AuthorID": "7006062408", "AffiliationID": "60009065, 60001563, 60057053", "AffiliationName": "Centrode Investigaciones Sobre Porfirinas Y Porfirias (CIPYP), Hospital de Cl\u00ednicas Jos\u00e9 de San Mart\u00edn, University of Buenos Aires"}, "6603296206": {"Name": "Giuntini F.", "AuthorID": "6603296206", "AffiliationID": "60030480", "AffiliationName": "Departmentof Pharmacy and Pharmacology, University of Bath"}, "56013223800": {"Name": "Eggleston I.", "AuthorID": "56013223800", "AffiliationID": "60030480", "AffiliationName": "Departmentof Pharmacy and Pharmacology, University of Bath"}, "6506148275": {"Name": "Vanzuli S.", "AuthorID": "6506148275", "AffiliationID": "60033276", "AffiliationName": "Instituto de Estudios Oncologicos, Academia Nacional de Medicina"}, "6701371551": {"Name": "Juarranz A.", "AuthorID": "6701371551", "AffiliationID": "60026796", "AffiliationName": "Departamento de Biolog\u00eda, Facultad de Ciencias, Universidad Aut\u00f3noma de Madrid"}, "26643365600": {"Name": "MacRobert A.", "AuthorID": "26643365600", "AffiliationID": "60022148", "AffiliationName": "Division of Surgery and Interventional Sciences, UCL Institute of Biomedical Engineering, University College London"}}}